Ariavax Overview

  • Founded
  • 2000

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Ariavax General Information


Developer of vaccines that are designed to selectively and specifically generate effective antibody-inducing immune responses. The company's vaccines are based on its proprietary peptide chemistry technology, providing users with vaccines that are safer, more stable and less expensive than current vaccines.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Primary Office
  • 708 Quince Orchard Road
  • Gaithersburg, MD 20878
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ariavax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jun-2013 Completed Out of Business
3. Grant 01-Feb-2009 00000 Completed Generating Revenue
2. Grant 01-May-2005 $218K Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Ariavax’s complete valuation and funding history, request access »